LAS VEGAS, NV / ACCESSWIRE / April 7, 2016 / Jim Cramer made a great point about investing in biotech's that I think is worth addressing. After the decline in the biotech industry last week, he announced he was a buyer. But, that's not the major point. He continued, expressing that there is huge risk involved in any biotech, but with that risk comes the opportunity for tremendous rewards.
It stands to reason that with the large amount of volatility in biotech companies it is worth taking a closer look at biotechs with lower prices per share, as there is plenty much more upside.
This is why we are taking a very close look at Propanc Health Group (OTCQB
PCH), who through its novel PRP treatment, is working toward clinical trials for pancreatic and ovarian cancers, followed by colorectal cancer.
Over the past year Propanc has made incredible strides toward achieving this goal, and just recently announced they received $1.2 million from an institutional investor in order to fast track its preclinical activities, including GMP (Good Manufacturing Practice) manufacturing and preparation for future patient trials, which the Company hopes to file an application for this year.
In an effort to keep the funding flowing the company announced their Chief Executive Officer, James Nathanielsz, is set to visit to New York City for meetings with institutional investors interested to learn more about the Company's future plans for growth. Proactive capital raising will help ensure there are no financial hiccups in PPCH's growth. This is huge for investors, and could cause a new influx of investors.
Since 2007, Propanc, an innovative biopharmaceutical company, has been working with extensive drug development and oncology and clinical experts, Professor Klaus Kutz and Dr. Julian Kenyon whose combined experience of more than 60 years in medicine has been critical in the research and development of PRP anti-cancer treatment. Klaus Kutz, CMO of Propanc, has prepared multiple investigational new drugs (IND) FDA applications, and Dr. Ralph Brandt of Propanc successfully led the tumor biology program for animal studies at Novartis. Dr Joseph Chalil, a recent addition to Propanc's Scientific Advisory Board, is a senior executive of Boehringer Ingleheim and a fellow of the American College of Healthcare Executives. The hope is this combination of experience will help them repeat their successes with Propanc.
There are several major events coming up that could be the catalyst for a major spike in share price: a scientific advice meeting with the MHRA (Medicines and Healthcare Products Regulatory Agency), UK, which has been confirmed towards the end of April, followed by a commitment to submit applications for orphan drug designation in the US and EU for pancreatic and ovarian cancers; investors are anticipating some large announcements in the near future and want to be in position to benefit before the secret is out on the enormous potential of PPCH.
With all of this going on it is no wonder that investors are loading the boat on PPCH. Now is not the time to sit on the sidelines.
It stands to reason that with the large amount of volatility in biotech companies it is worth taking a closer look at biotechs with lower prices per share, as there is plenty much more upside.
This is why we are taking a very close look at Propanc Health Group (OTCQB
PCH), who through its novel PRP treatment, is working toward clinical trials for pancreatic and ovarian cancers, followed by colorectal cancer. Over the past year Propanc has made incredible strides toward achieving this goal, and just recently announced they received $1.2 million from an institutional investor in order to fast track its preclinical activities, including GMP (Good Manufacturing Practice) manufacturing and preparation for future patient trials, which the Company hopes to file an application for this year.
In an effort to keep the funding flowing the company announced their Chief Executive Officer, James Nathanielsz, is set to visit to New York City for meetings with institutional investors interested to learn more about the Company's future plans for growth. Proactive capital raising will help ensure there are no financial hiccups in PPCH's growth. This is huge for investors, and could cause a new influx of investors.
Since 2007, Propanc, an innovative biopharmaceutical company, has been working with extensive drug development and oncology and clinical experts, Professor Klaus Kutz and Dr. Julian Kenyon whose combined experience of more than 60 years in medicine has been critical in the research and development of PRP anti-cancer treatment. Klaus Kutz, CMO of Propanc, has prepared multiple investigational new drugs (IND) FDA applications, and Dr. Ralph Brandt of Propanc successfully led the tumor biology program for animal studies at Novartis. Dr Joseph Chalil, a recent addition to Propanc's Scientific Advisory Board, is a senior executive of Boehringer Ingleheim and a fellow of the American College of Healthcare Executives. The hope is this combination of experience will help them repeat their successes with Propanc.
There are several major events coming up that could be the catalyst for a major spike in share price: a scientific advice meeting with the MHRA (Medicines and Healthcare Products Regulatory Agency), UK, which has been confirmed towards the end of April, followed by a commitment to submit applications for orphan drug designation in the US and EU for pancreatic and ovarian cancers; investors are anticipating some large announcements in the near future and want to be in position to benefit before the secret is out on the enormous potential of PPCH.
With all of this going on it is no wonder that investors are loading the boat on PPCH. Now is not the time to sit on the sidelines.
1
